Group 3 (G3) is one of the most common and aggressive subtypes of the paediatric cerebellar tumour Medulloblastoma (MB), primarily driven by the MYC oncogene. The challenging targeting of MYC, coupled with gaps in understanding G3 MB molecular bases, has hindered the development of targeted therapies. The unconventional oncogenic roles of long noncoding RNAs (lncRNAs) offer opportunities to address this complexity, to provide insights and to identify novel targets. Using -omics approaches and molecular/cellular assays, we elucidate the mode-of-action of lncMB3, a MYC-dependent, anti-apoptotic lncRNA in G3 MB. LncMB3 regulates the TGF-beta pathway, critically altered in G3 medulloblastomagenesis, via direct binding and translational inhibition of the mRNA for the epigenetic factor HMGN5. This regulatory axis affects apoptosis through photoreceptor lineage genes, including the G3 driver OTX2. The synergistic effects between lncMB3 targeting and cisplatin treatment underscore the relevance of this network. Additionally, we propose novel ferritin-based nanocarriers for the efficient delivery of antisense oligonucleotides against lncMB3. LncMB3 crucially links MYC amplification and apoptosis inhibition through a circuit involving RNA-based mechanisms, G3 MB key determinants and underexplored factors. This integrated framework deepens the understanding of G3 MB landscape and supports the potential for translating lncRNA research into future applications.

The impact of protein-coding genes on cancer onset and progression is a well-establishedparadigm in molecular oncology. Nevertheless, unveiling the contribution of the noncoding genes--including long noncoding RNAs (lncRNAs)--to tumorigenesis represents a great challenge forpersonalized medicine, since they (i) constitute the majority of the human genome, (ii) are essentialand flexible regulators of gene expression and (iii) present all types of genomic alterations describedfor protein-coding genes. LncRNAs have been increasingly associated with cancer, their highlytissue- and cancer type-specific expression making them attractive candidates as both biomarkersand therapeutic targets. Medulloblastoma is one of the most common malignant pediatric braintumors. Group 3 is the most aggressive subgroup, showing the highest rate of metastasis at diagnosis.Transcriptomics and reverse genetics approaches were combined to identify lncRNAs implicatedin Group 3 Medulloblastoma biology. Here we present the first collection of lncRNAs dependenton the activity of the MYC oncogene, the major driver gene of Group 3 Medulloblastoma. Weassessed the expression profile of selected lncRNAs in Group 3 primary tumors and functionallycharacterized these species. Overall, our data demonstrate the direct involvement of three lncRNAsin Medulloblastoma cancer cell phenotypes The impact of protein-coding genes on cancer onset and progression is a well-established paradigm in molecular oncology. Nevertheless, unveiling the contribution of the noncoding genes--including long noncoding RNAs (lncRNAs)--to tumorigenesis represents a great challenge for personalized medicine, since they (i) constitute the majority of the human genome, (ii) are essential and flexible regulators of gene expression and (iii) present all types of genomic alterations described for protein-coding genes. LncRNAs have been increasingly associated with cancer, their highly tissue- and cancer type-specific expression making them attractive candidates as both bi-omarkers and therapeutic targets. Medulloblastoma is one of the most common malignant pediatric brain tumors. Group 3 is the most aggressive subgroup, showing the highest rate of metastasis at diagnosis. Transcriptomics and reverse genetics approaches were combined to identify lncRNAs implicated in Group 3 Medulloblastoma biology. Here we present the first collection of lncRNAs dependent on the activity of the MYC oncogene, the major driver gene of Group 3 Medulloblastoma. We assessed the expression profile of selected lncRNAs in Group 3 primary tumors and functionally characterized these species. Overall, our data demonstrate the direct involvement of three lncRNAs in Medulloblastoma cancer cell phenotypes.